

Ingrid Simonitsch-Klupp

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4222405/publications.pdf>

Version: 2024-02-01

80
papers

1,828
citations

304743

22
h-index

315739

38
g-index

81
all docs

81
docs citations

81
times ranked

3335
citing authors

#	ARTICLE	IF	CITATIONS
1	CXCR4 PET/MRI for follow-up of gastric mucosa-associated lymphoid tissue lymphoma after first-line <i>Helicobacter pylori</i> eradication. <i>Blood</i> , 2022, 139, 240-244.	1.4	22
2	Difficulties in the differential diagnosis of large solitary pulmonary cysts. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2022, 34, 1157-1159.	1.1	3
3	Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders. <i>Cancer Discovery</i> , 2022, 12, 372-387.	9.4	77
4	The cancer survival index—A prognostic score integrating psychosocial and biological factors in patients diagnosed with cancer or haematologic malignancies. <i>Cancer Medicine</i> , 2022, 11, 3387-3396.	2.8	7
5	CXCR4 PET imaging of mantle cell lymphoma using [⁶⁸ Ga]Pentixafor: comparison with [¹⁸ F]FDG-PET. <i>Theranostics</i> , 2021, 11, 567-578.	10.0	26
6	CD38 Antibody Daratumumab for the Treatment of Chronic Active Antibody-mediated Kidney Allograft Rejection. <i>Transplantation</i> , 2021, 105, 451-457.	1.0	57
7	Rationale for the combination of venetoclax and ibrutinib in T-prolymphocytic leukemia. <i>Haematologica</i> , 2021, 106, 2251-2256.	3.5	7
8	Characteristics, management, and outcome of pediatric patients with post-transplant lymphoproliferative disease—A 20% years' experience from Austria. <i>Cancer Reports</i> , 2021, 4, e1375.	1.4	10
9	Single-Cell RNA Sequencing Reveals Tissue Compartment-Specific Plasticity of Mycosis Fungoides Tumor Cells. <i>Frontiers in Immunology</i> , 2021, 12, 666935.	4.8	27
10	Genetic Characterization and Clinical Features of <i>Helicobacter pylori</i> Negative Gastric Mucosa-Associated Lymphoid Tissue Lymphoma. <i>Cancers</i> , 2021, 13, 2993.	3.7	9
11	Molecular features of non-anaplastic peripheral T-cell lymphoma in children and adolescents. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29285.	1.5	6
12	Dose-adjusted EPOCH-rituximab or intensified B-NHL therapy for pediatric primary mediastinal large B-cell lymphoma. <i>Haematologica</i> , 2021, 106, 3232-3235.	3.5	8
13	Co-occurrence of immature T-lymphoblastic lymphoma and acute myeloid leukemia—microenvironment-dependent lineage differentiation derived from a common progenitor?. <i>Journal of Hematopathology</i> , 2021, 14, 325-332.	0.4	0
14	Super-enhancer-based identification of a BATF3/IL-2RA module reveals vulnerabilities in anaplastic large cell lymphoma. <i>Nature Communications</i> , 2021, 12, 5577.	12.8	21
15	Neuropathological Variability within a Spectrum of NMDAR-Encephalitis. <i>Annals of Neurology</i> , 2021, 90, 725-737.	5.3	35
16	Influence of TP53 Mutation on Survival of Diffuse Large B-Cell Lymphoma in the CAR T-Cell Era. <i>Cancers</i> , 2021, 13, 5592.	3.7	9
17	Molecular quantification of tissue disease burden is a new biomarker and independent predictor of survival in mastocytosis. <i>Haematologica</i> , 2020, 105, 366-374.	3.5	21
18	Treatment with brentuximab vedotin plus bendamustine in unselected patients with CD30-positive aggressive lymphomas. <i>European Journal of Haematology</i> , 2020, 104, 251-258.	2.2	12

#	ARTICLE	IF	CITATIONS
19	RECIL Versus Lugano for Treatment Response Assessment in FDG-Avid Non-Hodgkin Lymphomas: A Head-to-Head Comparison in 54 Patients. <i>Cancers</i> , 2020, 12, 9.	3.7	15
20	Biological properties of bone marrow plasma cells influence their recovery in aspirate specimens: impact on classification of plasma cell disorders and potential bias to evaluation of treatment response. <i>Annals of Hematology</i> , 2020, 99, 2599-2609.	1.8	4
21	First Line Systemic Treatment for MALT Lymphoma – Do We Still Need Chemotherapy? Real World Data from the Medical University Vienna. <i>Cancers</i> , 2020, 12, 3533.	3.7	4
22	Myelomonocytic Skewing In Vitro Discriminates Subgroups of Patients with Myelofibrosis with A Different Phenotype, A Different Mutational Profile and Different Prognosis. <i>Cancers</i> , 2020, 12, 2291.	3.7	3
23	Depth of Remission Following First-Line Treatment Is an Independent Prognostic Marker for Progression-Free Survival in Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma. <i>Cancers</i> , 2020, 12, 492.	3.7	7
24	Management of children and adolescents with gray zone lymphoma: A case series. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28206.	1.5	7
25	Treatment Guided By Next Generation Functional Drug Screening Provides Clinical Benefit in Advanced Aggressive Hematological Malignancies: Final Evaluation of the Open Label, Single Arm Exalt Trial. <i>Blood</i> , 2020, 136, 2-4.	1.4	1
26	Phase II Single-Arm "Window-of-Opportunity" Study of a Combination of Obinutuzumab and Venetoclax in Early Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) - First Results of the AGMT NHL15B Study. <i>Blood</i> , 2020, 136, 26-26.	1.4	0
27	Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma. <i>Leukemia</i> , 2019, 33, 696-709.	7.2	40
28	Prolonged follow-up on lenalidomide-based treatment for mucosa-associated lymphoid tissue lymphoma (MALT lymphoma) – Real world data from the Medical University of Vienna. <i>Hematological Oncology</i> , 2019, 37, 345-351.	1.7	11
29	Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia. <i>Blood</i> , 2019, 134, 1132-1143.	1.4	81
30	Epigenomics and Single-Cell Sequencing Define a Developmental Hierarchy in Langerhans Cell Histiocytosis. <i>Cancer Discovery</i> , 2019, 9, 1406-1421.	9.4	42
31	PD-L1 and PD1 expression in post-transplantation lymphoproliferative disease (PTLD) of childhood and adolescence: An inter- and intra-individual descriptive study covering the whole spectrum of PTLD categories. <i>Cancer Medicine</i> , 2019, 8, 4656-4668.	2.8	14
32	Gastrointestinal Involvement in Patients with Mantle Cell Lymphoma: A Single Center Experience of Eighty-Five Patients. <i>Digestive Diseases</i> , 2019, 37, 194-200.	1.9	9
33	Transformed mucosa-associated lymphoid tissue lymphomas: A single institution retrospective study including polymerase chain reaction-based clonality analysis. <i>British Journal of Haematology</i> , 2019, 186, 448-459.	2.5	16
34	Pre-Therapeutic Total Lesion Glycolysis on [18F]FDG-PET Enables Prognostication of 2-Year Progression-Free Survival in MALT Lymphoma Patients Treated with CD20-Antibody-Based Immunotherapy. <i>Molecular Imaging and Biology</i> , 2019, 21, 1192-1199.	2.6	11
35	Treatment of mucosa associated lymphoid tissue lymphoma with a long-term once-weekly regimen of oral azithromycin: Results from the phase II MALT – A trial. <i>Hematological Oncology</i> , 2019, 37, 22-26.	1.7	20
36	Imatinib +/- Brentuximab Vedotin Induces Sustained Complete Remission in Chemotherapy-Resistant Anaplastic Large Cell Lymphoma Expressing PDGFR. <i>Blood</i> , 2019, 134, 4037-4037.	1.4	1

#	ARTICLE	IF	CITATIONS
37	Ultra-early response assessment in lymphoma treatment: [18F]FDG PET/MR captures changes in glucose metabolism and cell density within the first 72 hours of treatment. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 931-940.	6.4	23
38	Successful Clarithromycin Monotherapy in a Patient with Primary Follicular Lymphoma of the Duodenum. <i>Case Reports in Oncology</i> , 2018, 11, 239-245.	0.7	4
39	Mutations outside the N-terminal part of RBCK1 may cause polyglucosan body myopathy with immunological dysfunction: expanding the genotype-phenotype spectrum. <i>Journal of Neurology</i> , 2018, 265, 394-401.	3.6	36
40	Bone Marrow Involvement in Malignant Lymphoma. <i>Academic Radiology</i> , 2018, 25, 453-460.	2.5	13
41	The WHO diagnostic criteria for polycythemia vera: role of red cell mass versus hemoglobin/hematocrit level and morphology. <i>Annals of Hematology</i> , 2018, 97, 1581-1590.	1.8	10
42	Concurrent Acute Myelofibrosis and Acute Lymphoblastic Leukemia in Childhood: Case Report and Review of the Literature. <i>Journal of Pediatric Hematology/Oncology</i> , 2018, 40, 235-237.	0.6	3
43	A pilot phase II study of ofatumumab monotherapy for extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT) lymphoma. <i>Hematological Oncology</i> , 2018, 36, 49-55.	1.7	12
44	Correlation between glycolytic activity on [18F]FDG PET and cell density on diffusion-weighted MRI in lymphoma at staging. <i>Journal of Magnetic Resonance Imaging</i> , 2018, 47, 1217-1226.	3.4	16
45	Immunohistochemical expression of cereblon and MUM1 as potential predictive markers of response to lenalidomide in extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma). <i>Hematological Oncology</i> , 2018, 36, 62-67.	1.7	12
46	Digital PCR: A Sensitive and Precise Method for KIT D816V Quantification in Mastocytosis. <i>Clinical Chemistry</i> , 2018, 64, 547-555.	3.2	49
47	miR-150 downregulation contributes to the high-grade transformation of follicular lymphoma by upregulating FOXP1 levels. <i>Blood</i> , 2018, 132, 2389-2400.	1.4	45
48	Impaired efferocytosis by monocytes in multiple myeloma. <i>Oncology Letters</i> , 2018, 16, 409-416.	1.8	9
49	Mutations affecting the actin regulator WD repeat-containing protein 1 lead to aberrant lymphoid immunity. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 1589-1604.e11.	2.9	64
50	Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy. <i>Blood</i> , 2018, 132, 694-706.	1.4	132
51	Molecular Quantification of Tissue Mast Cell Burden in Systemic Mastocytosis: A New Approach for Diagnostics and Prognostication. <i>Blood</i> , 2018, 132, 3043-3043.	1.4	0
52	Long-term safety and activity of cladribine in patients with extranodal B-cell marginal zone lymphoma of the mucosa-associated lymphoid tissue (MALT) lymphoma. <i>Hematological Oncology</i> , 2017, 35, 177-186.	1.7	6
53	Distinctive Histogenesis and Immunological Microenvironment Based on Transcriptional Profiles of Follicular Dendritic Cell Sarcomas. <i>Molecular Cancer Research</i> , 2017, 15, 541-552.	3.4	24
54	Pre-fibrotic/early primary myelofibrosis vs. WHO-defined essential thrombocythemia: The impact of minor clinical diagnostic criteria on the outcome of the disease. <i>American Journal of Hematology</i> , 2017, 92, 885-891.	4.1	47

#	ARTICLE	IF	CITATIONS
55	A phase 2 study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma. <i>Blood</i> , 2017, 129, 383-385.	1.4	51
56	Essential thrombocythemia vs. pre-fibrotic/early primary myelofibrosis: discrimination by laboratory and clinical data. <i>Blood Cancer Journal</i> , 2017, 7, 643.	6.2	11
57	Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study. <i>Lancet Haematology</i> , 2017, 4, e595-e606.	4.6	130
58	Recalcitrant rash in a six-month-old infant. <i>JDDG - Journal of the German Society of Dermatology</i> , 2017, 15, 1254-1257.	0.8	0
59	Targeted inhibition of the MAPK pathway: emerging salvage option for progressive life-threatening multisystem LCH. <i>Blood Advances</i> , 2017, 1, 352-356.	5.2	29
60	Identification of novel follicular dendritic cell sarcoma markers, FDCSP and SRGN, by whole transcriptome sequencing. <i>Oncotarget</i> , 2017, 8, 16463-16472.	1.8	43
61	Next-Generation Functional Drug Screening for Patients with Aggressive Hematologic Malignancies. <i>Blood</i> , 2017, 130, 855-855.	1.4	0
62	Evaluation of [18F]-FDG-Based Hybrid Imaging Combinations for Assessment of Bone Marrow Involvement in Lymphoma at Initial Staging. <i>PLoS ONE</i> , 2016, 11, e0164118.	2.5	10
63	12(S)-HETE increases intracellular Ca ²⁺ in lymph-endothelial cells disrupting their barrier function in vitro; stabilization by clinical drugs impairing calcium supply. <i>Cancer Letters</i> , 2016, 380, 174-183.	7.2	18
64	Prevalence of clarithromycin-resistant <i>Helicobacter pylori</i> strains in gastric mucosa-associated lymphoid tissue lymphoma patients. <i>Annals of Hematology</i> , 2016, 95, 1115-1120.	1.8	8
65	Insights into the Pathogenesis of Anaplastic Large-Cell Lymphoma through Genome-wide DNA Methylation Profiling. <i>Cell Reports</i> , 2016, 17, 596-608.	6.4	55
66	miRNA expression profiling divides follicular dendritic cell sarcomas into two groups, related to fibroblasts and myopericytomas or Castleman's disease. <i>European Journal of Cancer</i> , 2016, 64, 159-166.	2.8	16
67	Functional characterization, localization, and inhibitor sensitivity of the <i>TPR-FCFR1</i> fusion in 8p11 myeloproliferative syndrome. <i>Genes Chromosomes and Cancer</i> , 2016, 55, 60-68.	2.8	13
68	Delayed Efficacy After Treatment With Lenalidomide or Thalidomide in Patients With Mucosa-Associated Lymphoid Tissue Lymphoma. <i>Oncologist</i> , 2016, 21, 72-75.	3.7	15
69	Chondroid hamartoma of the lung presenting as cavern. <i>Clinical Respiratory Journal</i> , 2016, 10, 671-672.	1.6	0
70	Transformed mycosis fungoides: bridging to allogeneic stem cell transplantation with brentuximab vedotin. <i>Leukemia and Lymphoma</i> , 2016, 57, 206-208.	1.3	12
71	Prefibrotic Primary Myelofibrosis As an Entity Distinct from Other Philadelphia-Chromosome Negative Myeloproliferative Neoplasms - Data from the Austrian Reclassification Project. <i>Blood</i> , 2016, 128, 4252-4252.	1.4	2
72	Survival in Essential Thrombocythemia and Prefibrotic Primary Myelofibrosis - Correlation of Clinical Phenotype with Histomorphological Diagnosis. <i>Blood</i> , 2016, 128, 1932-1932.	1.4	0

#	ARTICLE	IF	CITATIONS
73	Evaluation of Diffusion-Weighted Magnetic Resonance Imaging for Follow-up and Treatment Response Assessment of Lymphoma: Results of an 18F-FDG-PET/CTâ€”Controlled Prospective Study in 64 Patients. <i>Clinical Cancer Research</i> , 2015, 21, 2506-2513.	7.0	78
74	Oncogenic role of <sc>miR</sc>â€”155 in anaplastic large cell lymphoma lacking the t(2;5) translocation. <i>Journal of Pathology</i> , 2015, 236, 445-456.	4.5	49
75	Clonal Mutational Landscape of Childhood Myelodysplastic Syndromes. <i>Blood</i> , 2015, 126, 1662-1662.	1.4	9
76	NF-Î”B contributes to MMP1 expression in breast cancer spheroids causing paracrine PAR1 activation and disintegrations in the lymph endothelial barrier <i>in vitro</i>. <i>Oncotarget</i> , 2015, 6, 39262-39275.	1.8	30
77	Clinical Impact of Bone Marrow Morphology for the Diagnosis of Essential Thrombocythemia: Comparison Between the British Standards (BCSH) and the WHO Criteria. <i>Blood</i> , 2015, 126, 2816-2816.	1.4	0
78	Evaluation of Diffusion-Weighted MRI for Pretherapeutic Assessment and Staging of Lymphoma: Results of a Prospective Study in 140 Patients. <i>Clinical Cancer Research</i> , 2014, 20, 2984-2993.	7.0	100
79	Lenalidomide induced response in a patient with follicular lymphoma of the skin and an anti-rituximab-antibody. <i>Memo - Magazine of European Medical Oncology</i> , 2013, 6, 123-126.	0.5	1
80	Favorable Survival of Multiple Myeloma Patients with t(11;14)(q13;q32) Plus Normal Chromosome 13q.. <i>Blood</i> , 2004, 104, 3459-3459.	1.4	0